Vimarsana
Biggest News Aggregation in the World

Page 6 - Rd Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rd Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rd Division Today - Breaking & Trending Today

Global Hemp : GHG Announces Brokered Private Placement - Vimarsana News

Global Hemp : GHG Announces Brokered Private Placement

2023 News Releases Apr 20, 2023 GHG Announces Brokered Private Placement Apr 4, 2023 GHG Final Payment on Exclusive... | April 20, 2023

Global Hemp Group Inc.: Global Hemp Group Announces Final Payment Made Relating to the Exclusive Licensing of Apollon Formularies PLC Patents and Intellectual Property - Vimarsana News

Global Hemp Group Inc.: Global Hemp Group Announces Final Payment Made Relating to the Exclusive Licensing of Apollon Formularies PLC Patents and Intellectual Property

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that it has completed its

Global Hemp : Announces Closing of 1st tranche of PP - Vimarsana News

Global Hemp : Announces Closing of 1st tranche of PP

2023 News Releases Mar 31, 2023 1st tranche PP Mar 30, 2023 Jeff Nagel joins as Product Manufacturing Advisor ... | April 1, 2023

Global Hemp Group Inc.: Global Hemp Group Announces Jeff Nagel as Product Manufacturing Advisor - Vimarsana News

Global Hemp Group Inc.: Global Hemp Group Announces Jeff Nagel as Product Manufacturing Advisor

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that Jeff Nagel has joined

Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer - Vimarsana News

Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer

Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.